NCT01079091

Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Hepa Wash GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.

Conditions

• Acute on Chronic Hepatic Failure

Interventions

Type	Name	Description
DEVICE	ADVOS (Hepa Wash)	Intervention frequency: 1-10 treatments (decision of the investigator) Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)
PROCEDURE	Standard Medical Therapy	Standard of care treatment

Timeline

• Start date: 2010-09-01
• Primary completion: 2013-07-01
• Completion: 2013-10-01
• First posted: 2010-03-02
• Last updated: 2019-07-05

Locations

1 site across 1 country: Germany